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The Lennox-Gastaut syndrome (LGS: the triad of intractable seizures of various 
types, a slow spike-wave pattern in EEG and mental retardation) is one of the 
most difficult epilepsy syndromes to treat. The aim of this study was to evaluate 
the efficacy and safety of zonisamide (ZNS) as add-on therapy in seizures of 
children with LGS. 
Materials & Methods
In a quasi- experimental study, seizure frequency and side effects of 40 children 
with LGS who were referred to the pediatric neurology clinic of Shaheed 
Sadoughi University of Medical Sciences, Yazd, Iran, between September 2008 
and November 2009 and were on ZNS for six months were evaluated.  
Results
Twenty one boys and 19 girls with a mean age of 6.6  3.6years were evaluated. 
At the end of six months of treatment with ZNS, 25% became seizure free, 25% 
had > 50% reduction in seizure frequency while 35% did not have a notable 
change in seizure frequency and 15% experienced an increase in seizure 
frequency.
Drug was effective in 62.5% of the myoclonic and generalized tonic-clonic, 
50% of the atonic, 43% of the mixed type and 33.4% of the tonic seizures. 
Transient side effects were seen in 25% of the patients: drowsiness in 10%, 
hyperthermia in 5 % and irritability, fatigue, ataxia and anorexia (each one) in 
2.5% of the patients. No serious side effects were reported. 
Conclusion 
ZNS could be considered as an add-on therapy in the management of intractable 
epilepsy in LGS.
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Introduction
Lennox-Gastaut syndrome (LGS) is one of the catastrophic epileptic syndromes of 
childhood. William Lennox described the clinical features of the syndrome in 1930s 
(1). This syndrome is characterized by the triad of intractable seizures of various 
types, psychomotor retardation and a slow (less than 2.5-hertz) spike-wave pattern 
in the waking electroencephalogram (EEG) and fast rhythmic bursts during sleep. 
LGS accounts for 1-10 percent of all cases of childhood epilepsy but is a major 
contributor to morbidity and seizures are often associated with falls and injuries (2). 
The onset of the seizures varies from 6 months to 16 years of age (3). 
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 Etiologic classification of LGS  includes:
1. Symptomatic: with identifiable prenatal, perinatal, 
and postnatal causes 
2. Idiopathic: with an unknown underlying cause 
in detailed investigations with normal psychomotor 
development at the onset of seizures. The term idiopathic 
has traditionally been used as cryptogenic (4).
Medical management of LGS is often difficult and 
seizures are mainly drug resistant. The cornerstone 
of treatment is antiepileptic drugs (AEDs), but other 
treatment methods of refractory seizures, including 
the ketogenic diet, intravenous immunoglobulin and 
surgical options (vagus nerve stimulation, corpus 
callosotomy, stereotactic surgical implantation of 
electrodes to the centromedian nuclei of the thalamus, 
etc.), may be used, as well. Different old and new AEDs 
such as benzodiazepines, carbamazepine, phenobarbital, 
primidone, phenytoin, valproate, zonisamide, topiramate, 
lamotrigine, felbamate, rufinamide, and levetiracetam 
have been used in LGS treatment. No single treatment 
regimen could be considered superior to others, and no 
study to date has shown one drug to be highly efficacious 
(4-6 ). 
Zonisamide (ZNS) is one of the broad spectrum 
AEDs which may be effective in pediatric partial 
and generalized seizures, especially for myoclonic 
epilepsies. Its effect is based on the following 
mechanisms:         
a) blocking voltage-dependent sodium channels     
b) blocking T-type calcium channels
c) blocking potassium-evoked glutamate responses
d) scavenging hydroxyl and nitric oxide radicals
e) increasing gamma-aminobutyric acid release from 
the hippocampus
f) inhibition of erythrocyte carbonic anhydrase (4,5,7,8) 
ZNS can be considered as a second-line drug in the 
treatment of infantile spasms, LGS and juvenile 
myoclonic epilepsy (9). The drug, as monotherapy or add 
- on therapy and in different dosages (1-20 mg/kg/day), 
has been used in the management of all seizure types 
and many epileptic syndromes of children in the United 
States, England, Japan, Korea, Italy, etc ( 7, 8, 10 - 15). 
Since ZNS usage is less frequent and little information 
is available regarding its efficacy in various epileptic 
syndromes in Iran, we decided to evaluate the efficacy 
and safety of Zonisamide in all seizure types of children 
with LGS in Yazd, Iran. 
Materials &Methods 
This quasi-experimental (before and after) study was 
conducted on children with LGS and refractory epilepsy 
who were referred to the pediatric neurology clinic of 
Shaheed Sadoughi University of Medical Sciences 
between September 2008 and November 2009 in Yazd, 
Iran. 
 Sample size was assessed to be 40 persons based
 on Z formula and a confidence interval of 95% with
 80% power, S= 30 and d=15 to detect any significant
difference between the two groups with a level of 0.05.
The diagnostic criteria for the LGS in this study were 
based on International League Against Epilepsy (ILAE) 
classification (16). In fact, patients were considered 
as control  group before, and case group after ZNS 
treatment. Care was taken to include LGS patients 
aged 1-18 years who had not responded to an adequate 
dosage of at least two conventional AEDS in single or 
combination, had at least one seizure in a week, were not 
sensitive to sulfonamide derivative, had not used ZNS 
formerly and maintained on ZNS for six months. 
Variables such age, sex, age at seizure onset, type and 
frequency of seizures (based on history), etiologic 
classification, family history of epilepsy in first and 
second degree relatives (based on history and direct 
interview with children's parents) and brain MRI results 
were reviewed. The trial had three phases as follows: 
1. Baseline phase: Seizure frequency per week in three 
months before adding ZNS was recorded. 
2. Titration phase: To minimize the side effects of the 
drug, ZNS was added to the previous AEDs regimen in 
a four-week period as follows: 4, 8, 12, 16 mg/kg/day in 
two divided doses.
3. Maintenance phase: Maximum dose or the one which 
controlled seizures continued for six months. No new 
AEDs were added to ZNS and concomitant drugs, but 
concomitant antiepileptic drugs were administered at 
sufficient dosages.
Patients were visited for six consecutive months and 
clinical information regarding the type and number of 
the seizures and side effects of the drug were recorded 
through interviewing their parents.
ZONISAMIDE IN LGS
47Iran J Child Neurology   Vol4 No3 Nov  2010
ZONISAMIDE IN LGS
At the end of the period, an electroencephalography 
(EEG) was done and ZNS efficacy and safety was 
evaluated. Seizure frequency in a week was compared 
to that of three months before and six months after ZNS 
use and the following classification was done on this 
basis: 
1. Seizure free: all the seizures stopped
2. Improved: more than 50 % reduction in seizure 
frequency
3. Unchanged: no notable change was seen in seizure 
frequency
4. Worsened: seizure frequency  increased more than 25%
It was impossible to check the serum level of Zonisamide 
in our center or any other center in Yazd. 
Chi-square or Fisher exact test were used for data analysis 
of qualitative variables and mean values were compared 
using T-test. Differences were considered significant at P 
values of less than 0.05. 
This study was approved by the Ethics Committee of 
Shaheed Sadoughi University of Medical Sciences, 
Yazd, Iran.
Results
The efficacy of ZNS was evaluated in 40 children with 
LGS and intractable seizures. Twenty one boys (52.5%) 
and 19 girls (47.5%) with a mean age of 6.6 ± 3.6 years 
(range = 1.5 -14 year) were included in this study.
Onset age of seizures was one month to 3 years (mean ± 
SD: 9.96 ± 8.16 month).
From the viewpoint of major seizure types, 14 children 
(35%) showed mixed type (more than one type of 
seizure), eight (20%) had generalized tonic-clonic 
(GTC), eight (20%) had myoclonic, six (15%) had tonic 
and four (10%) had atonic seizures.
Seizures were not controlled despite the usage of 4-15 
(mean ± SD: 8. 6 ± 2.8) antiepileptic drugs.
On the basis of etiologic classification, we noted 
symptomatic LGS in 31 (77.5%) and idiopathic LGS in 9 
(22.5%) patients. The etiology in the symptomatic group 
was structural CNS dysgenesia in 9, inborn errors of 
metabolism in 9, chromosomal abnormality and genetic 
syndromes in 4, hypoxic ischemic encephalopathy in 
4, tuberous sclerosis in 3 and congenital infection in 2 
children. 
 Brain MRI was normal in 19 (47%) children.  At the 
end of six months of ZNS treatment, 25% (N=10) of 
the patients became seizure free and 25% (N=10) had 
more than 50 % reduction in seizure frequency while 
35% (N=14) had no notable change in the frequency of 
seizures and seizure frequency increased> 25 % in six 
children. 
The mean dose of ZNS for seizure control was 11. 8 ± 
2.8 mg/kg/day (range: 4-16). 
 Results of efficacy analysis based on seizure type are 
shown in Table 1, indicating a good response to ZNS 
(all seizures stopped or more than 50 % reduction in 
seizure frequency) in 62.5 % of the myoclonic and GTC 
seizures, 50% of the atonic and 33.4 % of tonic seizures. 
Efficacy of the drug was not significantly different in 
different seizure types. 
For statistical analysis with Chi-square test GTCS, 
myoclonic, tonic and atonic seizures were considered 
as generalized seizures. Table 2 shows the frequency 
distribution of good response based on some clinical and 
paraclinical characteristics of patients, indicating that 
the drug has been more effective in girls and patients 
without drug side effects.
 Table 3 shows the comparison between mean age, age 
at seizure onset and seizure frequency three months 
before and six months after treatment based on etiologic 
classification, indicating that symptomatic LGS  was more 
in younger patients and that before and after treatment, 
seizure frequency was more in the symptomatic group. 
Transient and mild side effects were seen in 25% (N=10) 
of patients consisting of drowsiness in 10% (N=4), 
hyperthermia in 5 % (N=2) and irritability, fatigue, ataxia 
and anorexia, each in 2.5% (N= 1). All adverse effects 
occurred in the first or second week of the titration phase 
and disappeared in one or two weeks. No serious adverse 
events such as idiosyncratic skin reactions, metabolic 
acidosis or pancreatitis were seen.
Discussion
Management of LGS depends on the response of the 
patients and we are often forced to use two or more 
types of AEDs in combination. It is difficult to provide 
recommendations for the treatment of LGS in the 
absence of comparative trials. Therefore, AEDs with 
better efficacy and fewer side effects are fiercely needed. 
In this report, the efficacy and safety of Zonisamide in 
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children with LGS was evaluated.
In the present study, ZNS treatment controlled all seizures 
in 25% of the patients. However, this rate varies between 
4.8 % and 67% In other studies (8,11-13, 17-20). 
In this study, more than 50% reduction in seizure 
frequency was seen in 25% of the patients which is 
consistent with another study [29% (17)] while this rate 
varies between 22 % and 75.4% in other studies (8,11-
13, 17-24).
Possible explanations for this variety are ethnical and 
geographic differences, duration of follow-up, sample 
size, pharmacokinetic aspects, methods of patient 
selection, age range of the patient, etc. 
In our study, the drug was effective in 62.5% of the GTC 
and myoclonic seizures. In a study by Yamauchi, 58% 
of the patients with generalized seizures and 50% of the 
patients with myoclonic seizures showed improvement 
with Zonisamide treatment (25). In another study, 51.2% 
of the patients with generalized seizures and 55.6% of the 
patients who had myoclonic seizures showed a greater 
than 50% reduction in the frequency of seizures (8).
We noted that  ZNS was more effective in generalized 
seizures in comparison with mixed seizures. In a study 
by Park et al, evaluation of the efficacy and safety of 
ZNS monotherapy in epileptic patients showed that 
generalized seizures and partial seizures with or without 
secondary generalization were well controlled (19).
We also found that the mean dosage of ZNS for seizure 
control was 11.6 mg/Kg/day which is higher than 
other studies [5.7 (12), 7.7 (23), 8.2 (8), and 9.1 ( 20)]. 
Differences in race or drug pharmacokinetics may be 
responsible. 
In the present study, the drug was more effective in 
girls. One possible explanation for this discrepancy is 
that seizure onset is later and idiopathic LGS is more 
frequent in girls. However, other researches with longer 
follow-up periods and bigger sample sizes are required 
to answer this difference. 
In our study, ZNS adverse effects were seen in 25% of 
the children. Other studies, however, have reported rates 
between 4-80% (8,11-14,17-23,26). We also noted that 
the most common side effect, as also reported by other 
reports, was drowsiness (8,11,13, 22). 
The most common side effects that are documented in 
other studies include weight loss [13% (18) and 4.5% 
(17)], irritability and a reduced appetite (12), mental- 
psychiatric symptoms in 19.4% and gastrointestinal 
symptoms in 8.7% (26), decreased appetite, somnolence, 
and asthenia (22), memory loss in 35%, attention deficit 
in 27% and weight loss in 20% (19). Differences in race, 
age of the patients or drug pharmacokinetics may be 
responsible. 
In conclusion, ZNS could be considered as an add-on 
therapy in the management of intractable epilepsy in 
LGS.




Seizure free Improved Unchanged Worsened
Total
Number Percent Number percent Number Percent Number Percent
Mixed 3 21.5 3 21.5 5 35.5 3 21.5 14
GTC 3 37.5 2 25 2 25 1 12.5 8
 Myoclonic 2 25 3 37.5 2 25 1 12.5 8
Tonic 1 16.7 1 16.7 3 49.9 1 16.7 6
Atonic 1 25 1 25 2 50 0 0 4
P. value 0.96
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   Table 2: Frequency distribution of the good response based on some 
clinical and paraclinical characteristics of the patients  




 Number  Percent Number Percent
Sex
Female 13 68.4 6 31.6
0.03
Male 7 33.3 14 66.7
Seizure type Mixed 6 43 8 57 0.5
Generalized 14 54 12 46
Etiologic class Symptomatic 14 45 17 55 0.26
Cryptogenic 6 66.7 3 33.3
Family history of epilepsy
Yes 6 75 2 25
0.11
No 14 44 18 56
Brain MRI results 
 
Abnormal 8 38 13 62
0.16
Normal 12 63 7 37
Slow spike wave pattern in six 
months after treatment EEG
Yes 3 37.5 5 62.5
0.43
No 17 53 15 47
Occurrence of ZNS side effects
Yes 2 20 8 80
0.03
No 18 60 12 40
Table 3: Comparison of mean age, age at seizure onset and before 








 Age (in years) 5.97 ± 3.38 8.8 ± 3. 6 0.03
Age at seizure onset (in months) 9.01 ± 6.59 13.17 ± 12.03 0.18
 Seizure frequency before treatment (in weeks) 16.77 ± 15.65 2.72 ± 1.39 0.01
Seizure frequency after treatment (in weeks) 14.84 ± 2.98 2.03 ± 1.69 0.04
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